Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer
July 31 2017 - 4:15PM
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical
company developing small molecule therapeutics to treat diseases
caused by dysfunctional protein processing such as cystic fibrosis
(CF), today announced that it has appointed Helen M. Boudreau as
the Company’s Chief Financial Officer and Treasurer, effective July
25, 2017. Ms. Boudreau is stepping down as a Director from
the Proteostasis Board of Directors, a position she has held since
February 2016, to accept the executive management role.
“We are delighted that Helen has chosen to join
the Proteostasis management team,” said Meenu Chhabra, President
and Chief Executive Officer of Proteostasis. “Having had the
opportunity to serve with Helen on our board of directors for over
a year, I know firsthand that her insights on corporate strategy
and financial planning are second to none. With her already
intimate knowledge of the Company, I am confident that she will be
a tremendous asset as we continue advancing our later stage
development programs in CF, with the goal of enabling next
generation combinations anchored by our cystic fibrosis
transmembrane conductance regulator (CFTR) modulators, as well as a
proprietary triple combination therapy.”
“I’m extremely pleased to expand my role at
Proteostasis,” commented Ms. Boudreau. “Second generation CFTR
modulators hold the promise to improve treatment for broad groups
of cystic fibrosis patients, with the potential of this new class
of therapies and therapeutic combinations only just beginning to
emerge. Proteostasis has a deep pipeline of next generation
CFTR modulators that I look forward to seeing bear fruit in the
clinic.”
Helen Boudreau is a seasoned pharmaceutical
and biotechnology industry executive with a track record of
operational and financial achievements spanning more than 25 years.
In her most recent management role, she served as the Chief
Financial Officer of FORMA Therapeutics, Inc., a clinical stage
biotechnology company. From 2008 to 2014, Ms. Boudreau held a
variety of leadership roles with increasing responsibility at
Novartis, including serving as the Chief Financial Officer of
Novartis Corporation, the U.S. corporate arm of Novartis AG with
over $20 billion in revenue. Before joining Novartis,
Ms. Boudreau served in multiple leadership positions at
Pfizer, Inc., most recently as Vice President of Finance, Customer
Business Unit and Commercial Operations. Previously,
Ms. Boudreau held strategic and operational roles at Yum
Brands/PepsiCo., McKinsey & Company, and Bank of America.
Ms. Boudreau received a B.A. in Economics from the University
of Maryland and an M.B.A. from the Darden School at the University
of Virginia.
About Proteostasis Therapeutics,
Inc.
Proteostasis Therapeutics, Inc. is a
biopharmaceutical company dedicated to the discovery of
groundbreaking therapies to treat diseases caused by dysfunctional
protein processing, such as cystic fibrosis (CF). Headquartered in
Cambridge, MA, the Proteostasis Therapeutics team focuses on
identifying therapies that restore protein function. In addition to
its multiple programs in cystic fibrosis, Proteostasis Therapeutics
has formed a collaboration with Astellas Pharma, Inc. to research
and identify therapies targeting the Unfolded Protein Response
(UPR) pathway. For more information, visit
www.proteostasis.com.
Safe Harbor
To the extent that statements in this release
are not historical facts, they are forward-looking statements
reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words such as “aim,” “may,”
“will,” “expect,” “anticipate,” “estimate,” “intend,” and similar
expressions (as well as other words or expressions referencing
future events, conditions or circumstances) are intended to
identify forward-looking statements. Examples of
forward-looking statements made in this release include, without
limitation, statements regarding our clinical studies and cohorts
for PTI-428, PTI-801, PTI-808 and our triple combination therapy
candidate, PTI-NC-733. Forward-looking statements made
in this release involve substantial risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied by the forward-looking statements, and we
therefore cannot assure you that our plans, intentions,
expectations or strategies will be attained or achieved. Such
risks and uncertainties include, without limitation, the
possibility final or future results from our drug candidate trials
(including, without limitation, longer duration studies) do not
achieve positive results or are materially and negatively different
from or not indicative of the preliminary results reported by the
Company (noting that these results are on a small number of
patients and small data set), uncertainties inherent in the
execution and completion of clinical trials (including, without
limitation, the possibility FDA requires us to run cohorts
sequentially or conduct additional cohorts or pre-clinical or
clinical studies), in the enrollment of CF patients in our clinical
trials, in the timing of availability of trial data, in the results
of the clinical trials, in possible adverse events from our trials,
in the actions of regulatory agencies, in endorsement, if any, by
therapeutic development arms of CF patient advocacy groups, and
those set forth in our Annual Report on Form 10-K for the year
ended December 31, 2016, and our other SEC filings. We assume
no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACTS:
Investors:
David Pitts
Argot Partners
212.600.1902
david@argotpartners.com
Media:
Eliza Schleifstein
Argot Partners
973.361.1546
eliza@argotpartners.com
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Proteostasis Therapeutics (NASDAQ:PTI)
Historical Stock Chart
From Apr 2023 to Apr 2024